Last reviewed · How we verify
Idarubicine plus Cytarabine regimen
Idarubicine plus Cytarabine regimen is a Chemotherapy combination regimen (anthracycline + nucleoside analog) Small molecule drug developed by The First Affiliated Hospital of Soochow University. It is currently in Phase 3 development for Acute myeloid leukemia (AML), newly diagnosed or relapsed/refractory.
Idarubicin intercalates into DNA and inhibits topoisomerase II, while cytarabine inhibits DNA synthesis, together inducing apoptosis in leukemic cells.
Idarubicin intercalates into DNA and inhibits topoisomerase II, while cytarabine inhibits DNA synthesis, together inducing apoptosis in leukemic cells. Used for Acute myeloid leukemia (AML), newly diagnosed or relapsed/refractory.
At a glance
| Generic name | Idarubicine plus Cytarabine regimen |
|---|---|
| Sponsor | The First Affiliated Hospital of Soochow University |
| Drug class | Chemotherapy combination regimen (anthracycline + nucleoside analog) |
| Target | Topoisomerase II (idarubicin); DNA polymerase (cytarabine) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Idarubicin is a topoisomerase II inhibitor that intercalates into DNA and prevents strand religation, causing double-strand breaks. Cytarabine is a nucleoside analog that is phosphorylated intracellularly and incorporated into DNA, inhibiting DNA polymerase and blocking DNA synthesis. The combination exploits complementary mechanisms to maximize cytotoxicity against rapidly dividing leukemic blasts.
Approved indications
- Acute myeloid leukemia (AML), newly diagnosed or relapsed/refractory
Common side effects
- Myelosuppression (neutropenia, thrombocytopenia, anemia)
- Mucositis
- Nausea and vomiting
- Infection
- Cardiotoxicity
- Hepatotoxicity
- Neurotoxicity (cytarabine syndrome)
Key clinical trials
- Standard-dose vs Intermediate-dose Cytarabine Induction in the Treatment of Acute Myeloid Leukemia With RUNX1-RUNX1T1 (PHASE3)
- VAG Versus Standard Chemotherapy With FLT3 Inhibitor in Adult Patients With FLT3-Mutated AML (PHASE3)
- Venetoclax, Azacitidine, and Mitoxantrone Hydrochloride Liposome Versus Idarubicin and Cytarabine in Newly Diagnosed AML (PHASE3)
- A Multicenter RCT of "3+7" vs Venetoclax + CACAG in Newly Diagnosed Mid/High-Risk AML Patients (PHASE2)
- A Study of Bleximenib in Combination With Acute Myeloid Leukemia (AML) Directed Therapies (PHASE1)
- Comparison of VA and D/IA Induction Regimens in Elderly Fit Acute Myeloid Leukemia Patients (PHASE3)
- A Study of SNDX-5613 in Combination With Intensive Chemotherapy in Participants With Acute Myeloid Leukemias (PHASE1)
- Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Idarubicine plus Cytarabine regimen CI brief — competitive landscape report
- Idarubicine plus Cytarabine regimen updates RSS · CI watch RSS
- The First Affiliated Hospital of Soochow University portfolio CI
Frequently asked questions about Idarubicine plus Cytarabine regimen
What is Idarubicine plus Cytarabine regimen?
How does Idarubicine plus Cytarabine regimen work?
What is Idarubicine plus Cytarabine regimen used for?
Who makes Idarubicine plus Cytarabine regimen?
What drug class is Idarubicine plus Cytarabine regimen in?
What development phase is Idarubicine plus Cytarabine regimen in?
What are the side effects of Idarubicine plus Cytarabine regimen?
What does Idarubicine plus Cytarabine regimen target?
Related
- Drug class: All Chemotherapy combination regimen (anthracycline + nucleoside analog) drugs
- Target: All drugs targeting Topoisomerase II (idarubicin); DNA polymerase (cytarabine)
- Manufacturer: The First Affiliated Hospital of Soochow University — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Acute myeloid leukemia (AML), newly diagnosed or relapsed/refractory